论文部分内容阅读
目的:探讨西格列汀联合二甲双胍治疗2型糖尿病(T2DM)的疗效及安全性。方法选取2013年5月~2014年3月来我院就诊的2型糖尿病患者62例,所有患者随机分为治疗组(西格列汀联合二甲双胍治疗)32例和对照组(二甲双胍治疗)30例,观察两组患者治疗前及治疗12周后者空腹及餐后2小时血糖和胰岛素(FPG、2h PG、Fins、2hlns)、糖化血红蛋白(Hb Alc).计算胰岛β细胞功能指数(HOMA-β)、体重指数的变化。结果 0.05);治疗后两组患者与治疗前比较,差异均有统计学意义(P<0.05);且治疗后两组FBG、2h PG、Hb Alc、BMI、HOMA-β明显优于对照组,差异均有统计学意义(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论西格列汀联合二甲双胍治疗2型糖尿病疗效显著,可以有效降低患者的血糖,其安全性高,值得临床推广应用。
Objective: To investigate the efficacy and safety of sitagliptin and metformin in type 2 diabetes mellitus (T2DM). Methods Totally 62 patients with type 2 diabetes who were treated in our hospital from May 2013 to March 2014 were randomly divided into treatment group (sitagliptin plus metformin) 32 and control group (metformin 30) The fasting and postprandial blood glucose and insulin (FPG, 2h PG, Fins, 2hlns) and Hb Alc were measured before and 12 weeks after treatment in both groups, and the islet β cell function index (HOMA-β ), Changes in body mass index. (P 0.05). After treatment, the FBG, 2h PG, Hb Alc, BMI and HOMA-β in the two groups were significantly better than those in the control group (P 0.05) The differences were statistically significant (P <0.05). Adverse reactions between the two groups, the difference was not statistically significant (P> 0.05). Conclusion Sitagliptin combined with metformin treatment of type 2 diabetes significant effect, can effectively reduce the patient’s blood sugar, its high safety, worthy of clinical application.